These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 25397549)

  • 1. Simplification to Stribild vs continuation of RTV-boosted DRV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY-PI subgroup analysis.
    Arribas J; Rizzardini G; Arasteh K; Zurawski C; Dietz C; Pontani D; Garner W; Nguyen T
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19805. PubMed ID: 25397549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switch to Stribild versus continuation of NVP or RPV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY-NNRTI subgroup analysis.
    Stellbrink HJ; Antinori A; Pozniak A; Flamm J; Bredeek F; Patel K; Garner W; Piontkowsky D
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19793. PubMed ID: 25397537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants.
    Palella FJ; Fisher M; Tebas P; Gazzard B; Ruane P; Van Lunzen J; Shamblaw D; Flamm J; Ebrahimi R; Porter D; White K; Hindman J; Elbert E; De-Oertel S; Fralich T
    AIDS; 2014 Jan; 28(3):335-44. PubMed ID: 24670520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal safety profile of STB in virologically suppressed subjects from two randomized phase 3b switch trials.
    Reeves I; Fisher M; Kegg S; Arribas J; Dau L; Garner W; Walker I; Nguyen T
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19807. PubMed ID: 25397551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simplification to single-tablet regimen of elvitegravir, cobicistat, emtricitabine, tenofovir DF from multi-tablet ritonavir-boosted protease inhibitor plus coformulated emtricitabine and tenofovir DF regimens: week 96 results of STRATEGY-PI.
    Arribas JR; DeJesus E; van Lunzen J; Zurawski C; Doroana M; Towner W; Lazzarin A; Nelson M; McColl D; Andreatta K; Swamy R; Szwarcberg J; Nguyen T
    HIV Clin Trials; 2017 May; 18(3):118-125. PubMed ID: 28555519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term efficacy and safety of E/C/F/TDF vs EFV/FTC/TDF and ATV+RTV+FTC/TDF in HIV-1-infected treatment-naïve subjects ≥50 years.
    Gazzard B; Girard PM; Di Perri G; Gallant J; Towner W; Rogatto F; Demorin J; McColl D; Liu H; Rhee M; Szwarcberg J; Piontkowsky D
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19767. PubMed ID: 25397511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brief Report: Efficacy and Safety of Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF) in Virologically Suppressed Women.
    Hodder S; Squires K; Kityo C; Hagins D; Avihingsanon A; Kido A; Jiang S; Kulkarni R; Cheng A; Cao H
    J Acquir Immune Defic Syndr; 2018 Jun; 78(2):209-213. PubMed ID: 29481486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-Reported Symptoms over 48 Weeks in a Randomized, Open-Label, Phase 3b Non-inferiority Trial of Adults with HIV Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF Versus Continuation of Ritonavir-Boosted Protease Inhibitor with Emtricitabine and Tenofovir DF.
    Gathe J; Arribas JR; Van Lunzen J; Garner W; Speck RM; Bender R; Shreay S; Nguyen T
    Patient; 2015 Oct; 8(5):445-54. PubMed ID: 26286337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching from ritonavir to cobicistat in HIV patients with renal impairment who are virologically suppressed on a protease inhibitor.
    Fisher M; McDonald C; Moyle G; Martorell C; Ramgopal M; Laplante F; Curley J; Graham H; Tran-Muchowski C; Liu Y; Rhee M; Szwarcberg J
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19824. PubMed ID: 25397568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a randomized, double-blind, active-controlled phase 3 trial.
    Post FA; Yazdanpanah Y; Schembri G; Lazzarin A; Reynes J; Maggiolo F; Yan M; Abram ME; Tran-Muchowski C; Cheng A; Rhee MS
    HIV Clin Trials; 2017 May; 18(3):135-140. PubMed ID: 28303753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient-Reported Outcomes After a Switch to a Single-Tablet Regimen of Rilpivirine, Emtricitabine, and Tenofovir DF in HIV-1-Positive, Virologically Suppressed Individuals: Additional Findings From a Randomized, Open-Label, 48-Week Trial.
    Brunetta J; Moreno Guillén S; Antinori A; Yeni P; Wade B; Johnson M; Shalit P; Ebrahimi R; Johnson B; Walker I; De-Oertel S
    Patient; 2015 Jun; 8(3):257-67. PubMed ID: 25808940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baseline antiretroviral resistance mutations and treatment-emergent resistance in HIV-1 RNA-suppressed patients switching to EVG/COBI/FTC/TDF or continuing on their PI-, NNRTI-, or RAL-based regimen.
    Andreatta K; Kulkarni R; Abram ME; Nguyen T; Cao H; Miller MD; White KL
    J Acquir Immune Defic Syndr; 2015 Apr; 68(5):519-26. PubMed ID: 25559592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase IIIb, open-label single-arm trial of darunavir/cobicistat (DRV/COBI): Week 48 subgroup analysis of HIV-1-infected treatment-nave adults.
    Tashima K; Crofoot G; Tomaka FL; Kakuda TN; Brochot A; Vanveggel S; Opsomer M; Garner W; Margot N; Custodio JM; Fordyce MW; Szwarcberg J
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19772. PubMed ID: 25397516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simplification to co-formulated rilpivirine/emtricitabine/tenofovir in virologically suppressed patients: Data from a multicenter cohort.
    Pinnetti C; Di Giambenedetto S; Maggiolo F; Lorenzini P; Fabbiani M; Tommasi C; Latini A; Ammassari A; Loiacono L; Sterrantino G; Bellagamba R; Boumis E; Antinori A; Zaccarelli M
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19812. PubMed ID: 25397556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching to tenofovir/emtricitabine from abacavir/lamivudine in HIV-infected adults with raised cholesterol: effect on lipid profiles.
    Behrens G; Maserati R; Rieger A; Domingo P; Abel F; Wang H; Pearce G
    Antivir Ther; 2012; 17(6):1011-20. PubMed ID: 22910324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.
    Hill A; Sawyer W
    HIV Med; 2009 Oct; 10(9):527-35. PubMed ID: 19785663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults.
    Cohen C; Wohl D; Arribas JR; Henry K; Van Lunzen J; Bloch M; Towner W; Wilkins E; Ebrahimi R; Porter D; White K; Walker I; Chuck S; De-Oertel S; Fralich T
    AIDS; 2014 Apr; 28(7):989-97. PubMed ID: 24508782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cobicistat-boosted protease inhibitors in HIV-infected patients with mild to moderate renal impairment.
    McDonald CK; Martorell C; Ramgopal M; Laplante F; Fisher M; Post FA; Liu Y; Curley J; Abram ME; Custodio J; Graham H; Rhee MS; Szwarcberg J
    HIV Clin Trials; 2014; 15(6):269-73. PubMed ID: 25433666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naïve HIV-1-positive individuals: 96 week results from FLAMINGO.
    Molina JM; Clotet B; van Lunzen J; Lazzarin A; Cavassini M; Henry K; Kulagin V; Givens N; Brennan C; de Oliveira CF
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19490. PubMed ID: 25393999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of a reduced dose of DARUNAVIR/RTV in a cohort of antiretroviral-naïve and experienced HIV-infected patients: a medium-term follow-up.
    Lanzafame M; Lattuada E; Rigo F; Hill A; Vento S
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19822. PubMed ID: 25397566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.